alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with sulpiride in 6 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (sulpiride) | Trials (sulpiride) | Recent Studies (post-2010) (sulpiride) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 4,152 | 427 | 635 |
| Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | sulpiride (IC50) |
|---|---|---|---|
| Carbonic anhydrase 1 | Homo sapiens (human) | 1.2 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.04 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.019 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0858 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.2651 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.2215 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.62 | |
| D(2) dopamine receptor | Canis lupus familiaris (dog) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, BG; Kimes, AS; London, ED; Scheffel, U; Wilson, AA | 1 |
| Ciancone, MT; Haracz, JL; Rebec, GV; White, IM | 1 |
| Levant, B; Nemeroff, CB | 1 |
| Iwamoto, ET | 1 |
| Chiodo, LA; Freeman, AS; Zhang, J | 1 |
| Akiyama, K; Kuroda, S; Okumura, K; Ujike, H | 1 |
6 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and sulpiride
| Article | Year |
|---|---|
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
Topics: Animals; Autoradiography; Binding Sites; Binding, Competitive; Brain; Guanidines; Guinea Pigs; Iodobenzenes; Male; Mice; Receptors, sigma; Tissue Distribution | 1992 |
A lever-release version of the conditioned avoidance response paradigm: effects of haloperidol, clozapine, sulpiride, and BMY-14802.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Clozapine; Dextroamphetamine; Dose-Response Relationship, Drug; Haloperidol; Male; Psychotropic Drugs; Pyrimidines; Rats; Rats, Inbred Strains; Stereotyped Behavior; Sulpiride | 1992 |
Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: focus on haloperidol and BMY 14802.
Topics: Animals; Benzazepines; Brain; Drug Interactions; Haloperidol; Injections, Intraperitoneal; Male; Neurotensin; Psychotropic Drugs; Pyrimidines; Rats; Rats, Inbred Strains; Sulpiride | 1992 |
Evidence for a model of activation of central sigma systems.
Topics: Animals; Benzazepines; Benzomorphans; Butaclamol; Carbazoles; Dopamine Antagonists; Haloperidol; Kinetics; Male; Models, Biological; Motor Activity; Naltrexone; Narcotic Antagonists; Phenazocine; Pyrimidines; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, sigma; Sulpiride | 1989 |
Further characterization of the effects of BMY 14802 on dopamine neuronal activity.
Topics: Adrenergic alpha-Antagonists; Animals; Dopamine; Dopamine Agents; Ergolines; Injections, Intravenous; Iontophoresis; Male; Neurons; Piperidines; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Stereoisomerism; Sulpiride | 1993 |
BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats.
Topics: Animals; Antipsychotic Agents; Dibenzothiepins; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dystonia; Guanidines; Haloperidol; Male; Microinjections; Nerve Tissue Proteins; Perphenazine; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, sigma; Red Nucleus; Sulpiride; Torticollis | 1996 |